Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
32.39
Dollar change
+0.53
Percentage change
1.66
%
IndexRUT P/E15.33 EPS (ttm)2.11 Insider Own29.00% Shs Outstand57.03M Perf Week-4.06%
Market Cap1.88B Forward P/E10.17 EPS next Y3.18 Insider Trans-35.51% Shs Float40.49M Perf Month-4.28%
Income122.62M PEG0.60 EPS next Q0.65 Inst Own66.01% Short Float13.45% Perf Quarter-16.43%
Sales681.88M P/S2.75 EPS this Y7.32% Inst Trans-10.80% Short Ratio7.20 Perf Half Y11.50%
Book/sh10.46 P/B3.10 EPS next Y39.30% ROA14.38% Short Interest5.45M Perf Year-2.79%
Cash/sh7.08 P/C4.58 EPS next 5Y25.45% ROE22.75% 52W Range28.14 - 41.61 Perf YTD0.28%
Dividend Est.- P/FCF8.53 EPS past 5Y- ROI16.02% 52W High-22.16% Beta0.79
Dividend TTM- Quick Ratio3.20 Sales past 5Y546.41% Gross Margin75.16% 52W Low15.10% ATR (14)1.28
Dividend Ex-Date- Current Ratio3.24 EPS Y/Y TTM-14.96% Oper. Margin25.71% RSI (14)41.91 Volatility3.29% 3.39%
Employees246 Debt/Eq0.38 Sales Y/Y TTM25.83% Profit Margin17.98% Recom1.50 Target Price49.50
Option/ShortYes / Yes LT Debt/Eq0.28 EPS Q/Q25.17% Payout0.00% Rel Volume0.51 Prev Close31.86
Sales Surprise1.07% EPS Surprise18.81% Sales Q/Q16.08% EarningsOct 29 BMO Avg Volume756.17K Price32.39
SMA20-3.79% SMA50-5.55% SMA200-1.91% Trades Volume386,485 Change1.66%
Date Action Analyst Rating Change Price Target Change
Oct-10-24Resumed Raymond James Outperform
Sep-10-24Initiated UBS Buy $56
Jun-21-24Initiated Citigroup Buy $48
Jan-02-24Downgrade BofA Securities Neutral → Underperform $30
Sep-25-23Downgrade Goldman Neutral → Sell $40 → $31
Sep-07-23Initiated Berenberg Buy $59
Apr-20-23Initiated BofA Securities Neutral $35
Oct-14-22Upgrade Jefferies Hold → Buy $57 → $61
Oct-14-22Upgrade Janney Neutral → Buy $57 → $61
Aug-03-22Downgrade Jefferies Buy → Hold $57
Dec-03-24 08:05AM
Nov-21-24 08:05AM
Nov-01-24 09:40AM
Oct-30-24 10:30PM
06:00AM
03:06AM Loading…
03:06AM
02:26AM
Oct-29-24 05:15PM
04:12PM
04:00PM
08:40AM
07:30AM
Oct-22-24 10:01AM
Oct-16-24 08:05AM
Oct-14-24 09:51AM
12:14PM Loading…
Oct-11-24 12:14PM
Oct-09-24 05:02PM
Oct-03-24 11:11AM
Oct-01-24 08:45AM
Sep-29-24 04:43AM
Sep-27-24 05:23AM
Sep-26-24 08:05AM
Sep-25-24 09:40AM
Sep-24-24 12:00PM
Sep-21-24 02:26AM
Sep-10-24 02:56PM
Aug-26-24 09:40AM
Aug-21-24 08:05AM
Aug-16-24 12:20PM
Aug-14-24 09:55AM
09:40AM Loading…
Aug-09-24 09:40AM
Aug-06-24 09:15PM
08:45AM
07:30AM
Jul-23-24 08:05AM
Jul-19-24 09:55AM
Jul-17-24 09:50AM
Jul-09-24 06:00AM
Jul-01-24 02:18PM
Jun-25-24 08:05AM
08:05AM
Jun-24-24 12:56PM
07:00AM
Jun-05-24 08:05AM
May-28-24 08:05AM
May-01-24 12:45PM
11:07AM
Apr-30-24 05:45PM
01:44PM
11:54AM
10:54AM
09:12AM
07:05AM
07:00AM
Apr-16-24 08:05AM
Apr-11-24 08:05AM
Apr-03-24 08:05AM
Mar-26-24 08:05AM
Mar-19-24 01:26AM
Mar-08-24 09:38AM
Feb-28-24 08:05AM
Feb-23-24 11:58AM
Feb-22-24 11:57PM
03:30PM
08:45AM
08:12AM
07:30AM
Feb-21-24 08:05AM
Feb-20-24 08:05AM
Feb-12-24 09:28AM
Feb-08-24 08:05AM
Feb-07-24 12:36PM
Jan-23-24 09:55AM
04:16AM
Jan-12-24 09:55AM
Jan-08-24 08:05AM
Jan-05-24 09:55AM
Jan-04-24 12:00PM
Jan-03-24 08:05AM
Jan-02-24 06:38PM
Dec-17-23 12:03PM
Dec-07-23 08:53PM
08:05AM
Dec-05-23 01:02PM
08:05AM
Nov-29-23 09:55AM
Nov-16-23 08:05AM
Nov-15-23 08:05AM
Nov-13-23 09:55AM
Nov-08-23 09:40AM
08:05AM
Nov-06-23 09:50AM
Nov-03-23 11:40AM
Oct-31-23 06:00PM
09:38AM
08:40AM
07:30AM
Oct-26-23 08:05AM
Oct-25-23 10:02AM
Oct-24-23 10:00AM
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Valor IV Pharma Holdings, LLC10% OwnerNov 01 '24Sale30.304,000,000121,210,0007,218,033Nov 05 05:48 PM
Valor IV Pharma Holdings, LLC10% OwnerNov 05 '24Sale30.30600,00018,181,5006,618,033Nov 05 05:48 PM
Marshman Fund Trust II10% OwnerNov 01 '24Sale30.304,000,000121,210,0006,651,120Nov 05 04:05 PM
Marshman Fund Trust II10% OwnerNov 05 '24Sale30.30600,00018,181,5006,051,120Nov 05 04:05 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICEROct 29 '24Option Exercise24.0021,496515,90421,496Oct 31 04:45 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICEROct 29 '24Sale40.4721,496870,0180Oct 31 04:45 PM
JEFFREY G DIERKSOfficerOct 29 '24Proposed Sale35.7521,496768,482Oct 29 04:22 PM
JEFFREY G DIERKSOfficerOct 03 '24Proposed Sale35.5714,961532,163Oct 03 04:32 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICEROct 01 '24Option Exercise24.004009,600400Oct 02 04:06 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICEROct 01 '24Sale40.1940016,0770Oct 02 04:06 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICERSep 30 '24Option Exercise0.0060,000060,000Oct 02 04:05 PM
Kapadia SandipCHIEF FINANCIAL OFFICERSep 30 '24Option Exercise0.0060,000060,000Oct 02 04:04 PM
JEFFREY G DIERKSOfficerOct 01 '24Proposed Sale40.0021,796871,840Oct 01 04:35 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICERSep 30 '24Option Exercise24.0035,846860,30435,846Oct 01 04:07 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICERSep 30 '24Sale40.0335,8461,434,9510Oct 01 04:07 PM
JEFFREY G DIERKSOfficerSep 30 '24Proposed Sale39.137,175280,758Sep 30 04:28 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICERSep 27 '24Option Exercise24.002004,800200Sep 30 04:03 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICERSep 27 '24Sale40.052008,0090Sep 30 04:03 PM
JEFFREY G DIERKSOfficerSep 27 '24Proposed Sale39.7928,9711,152,756Sep 27 04:24 PM
Kapadia SandipCHIEF FINANCIAL OFFICERMar 29 '24Option Exercise0.0015,000015,000Apr 02 04:31 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICERMar 15 '24Option Exercise8.2211,97998,46711,979Mar 18 07:24 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICERMar 15 '24Sale32.0011,979383,3280Mar 18 07:24 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICERMar 08 '24Option Exercise8.221941,595194Mar 11 05:17 PM
Dierks JeffreyCHIEF COMMERCIAL OFFICERMar 08 '24Sale32.001946,2080Mar 11 05:17 PM